J Neurochem 73:390399 Kannan R, Yi JR, Tang D, Li Y, Zlokovic BV, Kaplowitz N (1996) Evidence for the existence of a sodium-dependent glutathione (GSH) transporter
As more patients are treated with these therapies, it is important to understand how they alter clinical presentations and risk for adverse effects
Semaglutide has been approved for use in managing type 2 diabetes (as in Ozempic), and it is available for weight loss in other forms (such as Wegovy)
For patients with FSA balances which typically expire at the end of the plan year under use-it-or-lose-it rules the Q4 window between October and December is an optimal time to apply expiring FSA funds to GLP-1 treatment costs rather than forfeiting them
ABSTRACT: Glucagon-like peptide-1 (GLP-1) agonists are a class of medications indicated for type 2 diabetes and obesity that may play a role in the management of cutaneous disease, in part due to their anti-inflammatory effects
